SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
A phase 2 trial of Tislelizumab and Cisplatin in oesophageal cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Overview
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07700667 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 120 participants planned, started 2026-08-13 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB500, Tislelizumab, Cisplatin and 5 - FU.
Similar pages
not linked directly; found by shared links- TrialA Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Shares Tislelizumab, Cisplatin, Oesophageal cancer and the tag pipeline.
- TrialA Study of SKB518 in Patients With Lung Cancer
Shares Sichuan Kelun-Biotech, Tislelizumab and the tag pipeline.
- TrialA Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Shares Tislelizumab, Cisplatin and the tag pipeline.
- TrialStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Shares Tislelizumab, Cisplatin and the tag pipeline.
- TrialSKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Study of KL590586 in Patients With Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Study of SKB571 in Patients With Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Shares Sichuan Kelun-Biotech and the tag pipeline.